Trial Profile
The study of TACE combined with apatinib for unresectable liver metastasis after colorectal cancer surgery
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 May 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- 30 May 2018 New trial record